EIK1005

Phase 2Small molecule

EEikon Therapeutics

EIK1005 is one of 2 small molecule programs targeting Microsatellite Instability High. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Microsatellite Instability HighRecruiting

Microsatellite Instability HighPhase 2

Recruiting

Competition

Competitive Landscape

1 competitor in Microsatellite Instability High

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

2 2

EIK1005

EEikon Therapeutics

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 1/2Recruiting

Microsatellite Instability High

NCT07262619

Clinical

Trials by Indication[1]

Microsatellite Instability High1 trial

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

Recruiting·EEikon Therapeutics·Phase 1/2·NCT07262619·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for EIK1005. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EIK1005 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EIK1005. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eikon Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EEikon Therapeutics

EIK1005

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Microsatellite Instability High1 trial

References

Drug Info

Quick Facts

Related News